Mangoceuticals (MGRX)
Market Price (2/15/2026): $0.4001 | Market Cap: $4.6 MilSector: Health Care | Industry: Health Care Technology
Mangoceuticals (MGRX)
Market Price (2/15/2026): $0.4001Market Cap: $4.6 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -77% | Weak multi-year price returns2Y Excs Rtn is -129%, 3Y Excs Rtn is -165% | Penny stockMkt Price is 0.4 |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Digital Health & Telemedicine, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4297% | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -38%, Rev Chg QQuarterly Revenue Change % is -37% | ||
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 268% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1264%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1264% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -434% | ||
| High stock price volatilityVol 12M is 139% | ||
| Key risksMGRX key risks include [1] severe financial distress and a high probability of bankruptcy, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -77% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Digital Health & Telemedicine, and E-commerce & DTC Adoption. Themes include Nutritional Supplements, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -129%, 3Y Excs Rtn is -165% |
| Penny stockMkt Price is 0.4 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -4297% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -38%, Rev Chg QQuarterly Revenue Change % is -37% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 268% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1264%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1264% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -434% |
| High stock price volatilityVol 12M is 139% |
| Key risksMGRX key risks include [1] severe financial distress and a high probability of bankruptcy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Mangoceuticals (MGRX) stock has lost about 80% since 10/31/2025 because of the following key factors:
1. Share Dilution from Recent Equity Offering: Mangoceuticals completed a registered direct offering and private placement on December 19, 2025, raising approximately $2.5 million through the sale of 1,930,502 common units. This offering contributed to a significant increase in the number of shares outstanding, which rose by 334.64% over the past year, thereby diluting existing shareholder value.
2. Weak Financial Performance and Profitability: The company has demonstrated persistent financial challenges, including a decline in earnings by 51.9% per year over the last five years. Mangoceuticals reported an EPS of -$0.69 for Q3 2025 and struggles with negative profitability metrics such as a Return on Equity (ROE) of -136.16% and a Return on Invested Capital (ROIC) of -78.35%. Furthermore, it faces issues with cash burn, short-term obligations, and generates less than $1 million in revenue.
Show more
1. Share Dilution from Recent Equity Offering: Mangoceuticals completed a registered direct offering and private placement on December 19, 2025, raising approximately $2.5 million through the sale of 1,930,502 common units. This offering contributed to a significant increase in the number of shares outstanding, which rose by 334.64% over the past year, thereby diluting existing shareholder value.
2. Weak Financial Performance and Profitability: The company has demonstrated persistent financial challenges, including a decline in earnings by 51.9% per year over the last five years. Mangoceuticals reported an EPS of -$0.69 for Q3 2025 and struggles with negative profitability metrics such as a Return on Equity (ROE) of -136.16% and a Return on Invested Capital (ROIC) of -78.35%. Furthermore, it faces issues with cash burn, short-term obligations, and generates less than $1 million in revenue.
Show more
Stock Movement Drivers
Fundamental Drivers
The -81.0% change in MGRX stock from 10/31/2025 to 2/14/2026 was primarily driven by a -75.7% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.08 | 0.40 | -81.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -9.5% |
| P/S Multiple | 40.2 | 9.8 | -75.7% |
| Shares Outstanding (Mil) | 10 | 12 | -13.4% |
| Cumulative Contribution | -81.0% |
Market Drivers
10/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MGRX | -81.0% | |
| Market (SPY) | -0.0% | 11.5% |
| Sector (XLV) | 9.3% | -6.5% |
Fundamental Drivers
The -76.4% change in MGRX stock from 7/31/2025 to 2/14/2026 was primarily driven by a -60.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.68 | 0.40 | -76.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -8.6% |
| P/S Multiple | 15.1 | 9.8 | -35.3% |
| Shares Outstanding (Mil) | 5 | 12 | -60.1% |
| Cumulative Contribution | -76.4% |
Market Drivers
7/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MGRX | -76.4% | |
| Market (SPY) | 8.2% | 15.1% |
| Sector (XLV) | 21.4% | -5.1% |
Fundamental Drivers
The -86.9% change in MGRX stock from 1/31/2025 to 2/14/2026 was primarily driven by a -82.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2142026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.02 | 0.40 | -86.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -38.2% |
| P/S Multiple | 8.1 | 9.8 | 21.1% |
| Shares Outstanding (Mil) | 2 | 12 | -82.5% |
| Cumulative Contribution | -86.9% |
Market Drivers
1/31/2025 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MGRX | -86.9% | |
| Market (SPY) | 14.3% | 14.6% |
| Sector (XLV) | 8.8% | 3.6% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/14/2026| Return | Correlation | |
|---|---|---|
| MGRX | ||
| Market (SPY) | 74.0% | 6.6% |
| Sector (XLV) | 23.7% | 3.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MGRX Return | - | - | -93% | -42% | -69% | -47% | -99% |
| Peers Return | -48% | -26% | 183% | 66% | 2% | -35% | 20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| MGRX Win Rate | - | - | 40% | 42% | 42% | 50% | |
| Peers Win Rate | 25% | 54% | 58% | 58% | 50% | 0% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MGRX Max Drawdown | - | - | -93% | -46% | -73% | -54% | |
| Peers Max Drawdown | -52% | -53% | -25% | -29% | -18% | -35% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HIMS, LFMD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
null
nullIn The Past
null
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Mangoceuticals (MGRX)
We plan to connect consumers to licensed healthcare professionals through our recently launched website at www.MangoRX.com for the provision of care via telehealth on our customer portal and plan to also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. To date, we have developed what we believe is a go-to-market strategy inclusive of product development, operations, marketing and advertising; however, we have not produced a significant amount of products and have generated only nominal revenues to date. We have identified men’s wellness telemedicine services and products as a growing sector in recent years and especially related to the areas of erectile dysfunction (“ED”) products. We have developed and are currently in the process of preparing to commercially market a new brand of ED product under the brand name “Mango.” This product is produced at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. This product currently includes the following three ingredients: Tadalafil (the active ingredient in Cialis) and Oxytocin, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs; and L-Arginine, an amino acid that is available as a dietary supplement. However, the fact that Tadalafil and Oxytocin are used in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to treat ED. We currently offer two dosage levels of our Mango ED product and anticipate doctors prescribing a dosage based on the needs and medical history of the patient. Our Mango ED product currently includes the following amounts of the three ingredients discussed above: (1) Tadalafil (10 milligrams (mg)), Oxytocin (100 International units (IU)) and L-Arginine (50mg); and (2) Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). Our Mango ED product has not been, and will not be, approved by the FDA and instead we plan to produce and sell our products, including our Mango ED product, under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act, as discussed below. We are not aware of any clinical studies involving the administration of tadalafil sublingually at the doses we provide patients, or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as is contemplated by our ED product. We are, however, aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of Tadalafil and Sildenafil (the active ingredient in Viagra). Additionally, because our Mango ED product is being specially compounded for the customer by a pharmacist with a physician’s prescription and because the ingredients for our Mango ED product will be publicly disclosed, this product formula can be replicated by other companies. Because our ED product has not been, and will not be, approved by the FDA, our product has not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur, we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties. We currently anticipate using approximately $1.8 million of the net proceeds of this offering to finance the marketing and operational expenses associated with the planned marketing of our Mango ED product. We launched our website in mid-November 2022. To date, we have sold only a small amount of products and generated only nominal revenues. We plan to market and seek to sell commercial quantities of our Mango ED product in the first quarter of 2023 following this offering. Mango has been formulated as a Rapid Dissolve Tablet (“RDT”) using a sublingual (applied under the tongue) delivery system to bypass the stomach and liver. It is a generally established principle that sublingual drug absorption through the oral mucosa is generally faster than drug absorption through the gastrointestinal tract. This is because sublingual drugs that are absorbed through the oral mucosa directly enter the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver (see H. Zhang et al., Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications, 41 Clin Pharmacokinet 661, 662 (2002). Though the active ingredients that comprise our Mango product are meant to treat ED – an issue that according to a 2018 study published in The Journal of Sexual Medicine has been estimated to affect over one-third of today’s men’s population (with prevalence increasing with age) – we are also aiming to brand ourselves as a lifestyle company marketed to men seeking enhanced sexual vitality, performance, and overall mood and confidence. Mango is expected to be sold exclusively online via our recently launched website at www.MangoRX.com. Our principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248, and our telephone number is (214) 242-9619. Our principal website address is www.mangorx.com. The Company was formed as a Texas corporation on October 7, 2021. At the time of the formation of the Company, the Company was wholly-owned by American International. Jacob D. Cohen, our Chairman and Chief Executive Officer, holds majority voting control over American International and also serves as the Chief Executive Officer, President and a member of the Board of Directors of American International. American International formed the Company with the intent of focusing on developing, marketing and selling a variety of men’s wellness products and services via a telemedicine platform. On June 16, 2022, American International entered into and closed the transactions contemplated by a Stock Purchase Agreement (the “SPA”) with Cohen Enterprises, Inc. (“Cohen Enterprises”), which is owned by Mr. Cohen, the Chairman and Chief Executive Officer of the Company, and who is also the majority shareholder of the Company. American International determined to divest its interests in the Company in order to focus on developing its pharmacy business through its 51% ownership of Epiq Scripts, which entity the Company has entered into the Master Services Agreement.
AI Analysis | Feedback
Analogies for Mangoceuticals (MGRX):
- Hims & Hers for men's specific wellness needs like ED and hair loss.
AI Analysis | Feedback
- Manco: A dietary supplement specifically formulated to support male sexual health and performance.
- Nutraceuticals: A range of dietary supplements designed to provide various health benefits beyond basic nutrition.
AI Analysis | Feedback
Mangoceuticals (MGRX) - Major Customers
Mangoceuticals (MGRX) primarily sells its products directly to individuals through its telehealth platform and direct-to-consumer model. The company focuses on men's health and wellness, particularly in areas requiring discreet and convenient solutions.
The up to three categories of individual customers that Mangoceuticals serves are:
- Men seeking solutions for Erectile Dysfunction (ED): This core customer segment is targeted by Mangoceuticals' flagship product, "MANGO." These individuals prioritize discreet, convenient, and effective treatment options for ED, often utilizing telemedicine services for consultation and prescription.
- Men experiencing hair loss or thinning: This customer group is addressed by products like "MANSCAPING," which focuses on preventing hair loss and promoting hair regrowth. These customers are looking for accessible and effective treatments for male pattern baldness and other hair-related concerns.
- Men interested in general men's health and wellness through a telehealth platform: Beyond specific conditions, Mangoceuticals' direct-to-consumer, telehealth-enabled model appeals to men seeking convenient and private access to healthcare professionals for various men's health concerns. While currently focused on ED and hair loss, this category represents the broader appeal of their service delivery method for overall male vitality and well-being.
AI Analysis | Feedback
- Compound Pharmaceutical Solutions
AI Analysis | Feedback
Jacob Cohen, Co-Founder, Chief Executive Officer, and Chairman
Jacob Cohen is a serial entrepreneur with over 20 years of experience in investment banking and capital markets, having co-founded and grown multiple companies across various sectors, including marketing, advertising, healthcare, IT, and financial services. Prior to co-founding Mangoceuticals, Inc., he was a co-founder and managing partner of several boutique investment bank and strategic advisory firms, where he advised companies on raising capital in both private and public markets. Cohen previously served as the Chief Financial Officer of The Renewed Group, Inc. and as Executive Vice President and Controller of Metiscan, Inc. During his tenure at Metiscan, he was instrumental in restructuring, reorganizing, and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing. While he has extensive experience in capital markets and advising companies on raising capital, the provided information does not explicitly state if he sold companies he was previously involved with to an acquirer or if he has a pattern of managing companies specifically backed by private equity firms.
Eugene M. Johnston, Chief Financial Officer
Eugene M. Johnston has served as Chief Financial Officer of Mangoceuticals, Inc. since October 2022. Since February 2015, Johnston has been the Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, he served as Chief Executive Officer of Peoplesway.com, Inc., a company specializing in skincare and nutritional products. The provided information does not explicitly state if he sold companies he was previously involved with to an acquirer or if he has a pattern of managing companies backed by private equity firms.
Amanda Hammer, Chief Operating Officer
Amanda Hammer serves as the Chief Operating Officer of Mangoceuticals, Inc.
AI Analysis | Feedback
Mangoceuticals (MGRX) faces several critical risks to its business, primarily stemming from its precarious financial health, significant regulatory and reputational challenges, and inherent market volatility.Key Risks to Mangoceuticals (MGRX)
- Financial Health and Solvency: Mangoceuticals exhibits severe financial distress, highlighted by substantial negative operating and net margins of -2772.43% and -2757.67% respectively. The company's Altman Z-Score of 1.75 places it within the distress zone, indicating a potential risk of bankruptcy within the next two years. Furthermore, the company has reported no revenue growth over the past three years and possesses less than a year of cash runway based on its current free cash flow, underscoring significant liquidity constraints with both its current and quick ratios at 0.07.
- Regulatory and Reputational Risks: The company's credibility and investor trust have been significantly undermined by its recent stock plunge following denials from Eli Lilly and Novo Nordisk regarding previously announced partnerships for weight-loss drugs. This incident raises concerns about potential misrepresentation. Additionally, Mangoceuticals has launched an investigation into potential stock manipulation linked to highly irregular trading patterns and an unprecedented surge in shareholder accounts after a recent reverse stock split. These issues could lead to regulatory scrutiny, increased stock volatility, and a further erosion of investor confidence. Operating in the healthcare sector, Mangoceuticals also faces ongoing regulatory pressures, including risks related to its products not being approved by the U.S. Food and Drug Administration (FDA) and potential non-compliance with FDA compounding exemptions.
- Market Volatility and Potential Shareholder Dilution: MGRX stock is subject to significant price fluctuations, with a volatility of 96.99. The company has received notices concerning non-compliance with Nasdaq's minimum bid price requirements, and a potential delisting from Nasdaq could severely impact its business, reduce stock price, decrease liquidity, and hinder its ability to attract new investors or raise capital. Moreover, the potential sale of common stock under an Equity Line of Credit (ELOC) could lead to significant dilution for existing shareholders.
AI Analysis | Feedback
The increasing interest and potential entry of large, established pharmaceutical companies into the medical cannabis and psychedelic therapeutics space represents a clear emerging threat for smaller, specialized biotech companies like Mangoceuticals. As regulatory barriers ease and the market legitimizes, these larger companies possess significantly greater R&D budgets, established clinical trial infrastructure, extensive regulatory experience, and vast marketing and distribution networks. This could lead to a highly competitive environment where MGRX may struggle to compete on product development, market penetration, or even in attracting talent and investment, similar to how Netflix's model disrupted Blockbuster's traditional business or the iPhone fundamentally altered the smartphone market dominated by BlackBerry at the time.
AI Analysis | Feedback
Mangoceuticals (MGRX) operates in several men's and women's wellness markets through its telemedicine platform. The addressable market sizes for their main products and services are as follows:
Erectile Dysfunction (ED) Products (Mango brand)
- Global: The global erectile dysfunction drugs market was valued at approximately USD 2.93 billion in 2024 and is projected to reach around USD 6.74 billion by 2034. Other estimates place the global market at USD 3.7 billion in 2024, growing to over USD 9.2 billion by 2035.
- U.S.: The U.S. erectile dysfunction drugs market size was valued at approximately USD 1.09 billion in 2024 and is expected to reach around USD 2.55 billion by 2034. Another source reported the U.S. market size as USD 1.48 billion in 2024.
Hair Loss Products (Grow brand)
- Global: The global hair loss treatment products market was valued at approximately USD 2.49 billion in 2024 and is projected to reach USD 3.57 billion by 2032. The broader global alopecia market, which includes therapeutics, was estimated at USD 9.48 billion in 2024 and is projected to reach USD 16.02 billion by 2030.
- U.S.: The U.S. Alopecia (Hair Loss) Therapeutics Market was valued at approximately USD 3.44 billion in 2022 and is predicted to grow to USD 5.29 billion by 2030.
Testosterone Replacement Therapy (TRT) (Prime brand)
- Global: The global testosterone replacement therapy market was valued at approximately USD 1.9 billion in 2024 and is expected to reach USD 2.9 billion by 2032. Another report estimated the market at USD 2.05 billion in 2025, reaching USD 2.51 billion by 2030.
- U.S.: The U.S. testosterone replacement therapy market accounted for approximately USD 736.1 million in 2024. North America, as a region, held approximately 48% of the global testosterone replacement therapy market in 2024.
Weight Loss Products (Slim brand, including Semaglutide)
- Global (GLP-1 Receptor Agonists Market): The global GLP-1 receptor agonist market, which includes Semaglutide, was estimated at approximately USD 53.46 billion in 2024 and is projected to reach USD 156.71 billion by 2030. Other forecasts indicate the global GLP-1 receptor agonist market could reach USD 147 billion by 2033 or around USD 268.37 billion by 2034. The global anti-obesity drugs market (broader) was around USD 15 billion in 2024 and could reach USD 150 billion by 2035.
- U.S. (GLP-1 Receptor Agonists Market): The U.S. GLP-1 receptor agonist market generated approximately USD 26.61 billion in 2023 and is expected to reach USD 133.24 billion by 2030. The U.S. prescription obesity drugs market soared to USD 26.4 billion by 2024. The U.S. obesity drugs market was valued at USD 6.68 billion in 2024 and is projected to reach USD 60.66 billion by 2033.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Mangoceuticals (MGRX) over the next 2-3 years:
-
Expansion of Men's Health and Wellness Product Portfolio and Customer Acquisition
Mangoceuticals, operating under the MangoRx brand, is continuously seeking to expand its customer base and enhance revenue streams through the development, marketing, and distribution of a variety of men's health and wellness products via its telemedicine platform. This includes existing offerings for erectile dysfunction (Mango), hair loss (Grow), hormone balance (Mojo), and weight loss (Slim). A specific recent initiative is the launch of "Prime by MangoRx," a telehealth-enabled testosterone replacement therapy utilizing Kyzatrex™, an FDA-approved oral testosterone capsule. The company's strategy involves actively expanding its direct-to-clinic sales division, enabling medical professionals to directly prescribe MangoRx products. -
Launch and Growth of Women's Telehealth Brand (PeachesRx)
Mangoceuticals has expanded its market reach by announcing the launch of "PeachesRx," a new women's telehealth brand. This platform will focus on personalized wellness and initially specialize in GLP-1 receptor agonists for weight loss treatments. This strategic move targets the expanding GLP-1 market, where a significant portion of weight loss prescriptions are for women, thereby opening up a substantial new revenue stream. -
Diversification through Strategic Intellectual Property Acquisitions into New Health Verticals
The company is aggressively diversifying its product offerings through strategic intellectual property (IP) acquisitions, moving beyond its foundational men's wellness products into high-growth health and wellness verticals.- Respiratory Illness Prevention Technology: In April 2024, Mangoceuticals acquired patents from Intramont Technologies related to respiratory illness prevention technology, including the antiviral compound MGX-0024. This compound is undergoing Phase II clinical trials and efficacy studies, with results anticipated in the third quarter of 2025. Successful commercialization of this technology, especially for applications like combating avian flu in poultry, could create significant new revenue streams.
- Plant-Based Skincare (Dermytol): Mangoceuticals secured a Master Distribution Agreement for Dermytol in January 2025, a brand of plant-based formulations targeting hyperpigmentation and skin brightening. Operations are expected to commence in Q3 2025, with MGRX holding exclusive distribution rights for North and South America in the growing global skincare market.
- Mushroom Nutraceuticals: MGRX is also actively diversifying into the mushroom nutraceuticals market.
-
Geographic Expansion into Asia Pacific and Latin American Markets
Mangoceuticals has secured a strategic partnership with the International Society of Frontier Life Sciences and Technology (ISFLST) to distribute its products in China, the Asia Pacific region, and Latin America (excluding Mexico). This agreement is a significant step in MangoRx's expansion strategy, aiming to introduce its men's health solutions to these rapidly growing international markets and enhance brand visibility and product adoption. The company identifies the substantial addressable market, particularly in China with an estimated 400 million males aged 35 and above, as a key growth opportunity.
AI Analysis | Feedback
Share Issuance
- Mangoceuticals closed its initial public offering (IPO) on March 23, 2023, issuing 1,250,000 shares at $4.00 per share, which generated $5,000,000 in gross proceeds.
- On August 26, 2025, the company sold 709,677 shares of restricted common stock to accredited investors, raising a total of $1,100,000.
- Mangoceuticals issued 70,454 shares of common stock along with warrants on May 15, 2025, raising $116,249 from investors.
Inbound Investments
- The company successfully completed its Initial Public Offering on March 23, 2023, resulting in $5,000,000 in gross proceeds.
- On August 26, 2025, Mangoceuticals received $1,100,000 from accredited investors through the sale of restricted common stock.
- Shareholders' equity was influenced by the issuance of Series B and Series C Convertible Preferred Stock, which include liquidation preferences and accrue dividends, as reported on November 14, 2024.
Capital Expenditures
- Funds from the March 2023 IPO were earmarked for marketing, operational expenses related to the ED drug 'Mango,' personnel hiring, and software development.
- As of September 30, 2024, a decrease in cash was attributed to operating expenses and investments in business expansion.
- Effective November 1, 2025, the company entered a five-year lease agreement for new office space with a monthly base rent of $4,852, prepaying $6,141 for the first month's rent and additional rent, and posting a $14,557 security deposit.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Mangoceuticals Earnings Notes | 12/16/2025 | |
| With Mangoceuticals Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.78 |
| Mkt Cap | 0.1 |
| Rev LTM | 251 |
| Op Inc LTM | -2 |
| FCF LTM | -0 |
| FCF 3Y Avg | 1 |
| CFO LTM | 13 |
| CFO 3Y Avg | 12 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 30.2% |
| Rev Chg 3Y Avg | 50.0% |
| Rev Chg Q | 13.0% |
| QoQ Delta Rev Chg LTM | 2.8% |
| Op Mgn LTM | -0.8% |
| Op Mgn 3Y Avg | -8.2% |
| QoQ Delta Op Mgn LTM | -1.0% |
| CFO/Rev LTM | 5.0% |
| CFO/Rev 3Y Avg | 5.8% |
| FCF/Rev LTM | -0.1% |
| FCF/Rev 3Y Avg | 0.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 1.7 |
| P/EBIT | -0.2 |
| P/E | -0.2 |
| P/CFO | 10.2 |
| Total Yield | -5.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.9% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -40.4% |
| 3M Rtn | -55.9% |
| 6M Rtn | -64.6% |
| 12M Rtn | -73.0% |
| 3Y Rtn | 41.1% |
| 1M Excs Rtn | -40.9% |
| 3M Excs Rtn | -58.0% |
| 6M Excs Rtn | -71.1% |
| 12M Excs Rtn | -77.8% |
| 3Y Excs Rtn | -29.1% |
Price Behavior
Price Behavior
| Market Price | $0.40 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/21/2023 | |
| Distance from 52W High | -92.9% | |
| 50 Days | 200 Days | |
| DMA Price | $0.73 | $1.59 |
| DMA Trend | down | down |
| Distance from DMA | -46.0% | -75.1% |
| 3M | 1YR | |
| Volatility | 151.3% | 139.6% |
| Downside Capture | 432.53 | 250.61 |
| Upside Capture | -345.73 | -37.84 |
| Correlation (SPY) | 5.2% | 15.8% |
MGRX Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.68 | -3.32 | 0.79 | 1.61 | 0.96 | 0.54 |
| Up Beta | -13.66 | -14.70 | -5.34 | -1.24 | 0.45 | -0.24 |
| Down Beta | -0.04 | -1.04 | 6.44 | 4.35 | 1.86 | -0.10 |
| Up Capture | -628% | -563% | -350% | -86% | -24% | -6% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 5 | 17 | 24 | 58 | 114 | 314 |
| Down Capture | 750% | 211% | 347% | 270% | 138% | 109% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 15 | 23 | 35 | 64 | 128 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MGRX | |
|---|---|---|---|---|
| MGRX | -91.0% | 139.7% | -0.99 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 4.4% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 15.8% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | -0.3% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | -1.1% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 12.1% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 11.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MGRX | |
|---|---|---|---|---|
| MGRX | -63.1% | 149.2% | -0.47 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 3.1% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 6.6% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 2.9% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | -1.6% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 5.6% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MGRX | |
|---|---|---|---|---|
| MGRX | -39.2% | 149.2% | -0.47 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 3.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 6.6% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 2.9% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | -1.6% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 5.6% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/15/2024 | -2.7% | -12.3% | -17.9% |
| 10/19/2023 | 25.0% | 10.3% | -36.7% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 0 |
| # Negative | 1 | 1 | 2 |
| Median Positive | 25.0% | 10.3% | |
| Median Negative | -2.7% | -12.3% | -27.3% |
| Max Positive | 25.0% | 10.3% | |
| Max Negative | -2.7% | -12.3% | -36.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 10/27/2023 | 10-Q |
| 06/30/2023 | 07/28/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | S-1/A |
| 09/30/2022 | 01/13/2023 | S-1 |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Johnston, Eugene M | CFO | Direct | Sell | 12172025 | 1.17 | 3,333 | 3,884 | 139,836 | Form |
| 2 | Johnston, Eugene M | CFO | Direct | Sell | 12112025 | 1.20 | 5,000 | 5,975 | 147,383 | Form |
| 3 | Johnston, Eugene M | CFO | Direct | Sell | 12092025 | 1.13 | 10,000 | 11,280 | 144,760 | Form |
| 4 | Hamilton, Alex P | Direct | Sell | 11262025 | 1.22 | 125,000 | 152,875 | 4,077 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.